Importantly, because maternal BMI is potentially modifiable (at least in the short term) through diet, exercise [51], and/or a glucagon-like peptide-1 receptor agonist [52] (e.g., semaglutide), this work holds promise in contributing to an improved understanding of plausible intervention targets to prevent or attenuate the intergenerational transfer of obesity risk. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.